Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
“SMALL-CAP - LOSERS
TT Electronics PLC, down 2.9% at 247.50 pence, 12-month range 198.50p-290.00p. Warns on supply chain blockages and guides for profit to be at the bottom end of market expectations. Revenue in the four months to October is 11% higher than the previous year on a constant currency basis and 8% higher on an organic basis. Says order intake continues to "run well ahead" of strongly growing revenue, with book to bill of 140%. As a result, order book is at record levels and provides "excellent visibility" into 2022. "Global supply chain constraints have continued in the second half and in some areas have tightened, principally impacting Power and Connectivity. The increased material and freight costs are being broadly offset by efficiencies and price management and supported by the self-help programme which continues to progress well, and we remain on track to deliver the anticipated run-rate benefits of GBP11 million to GBP12 million in 2023," company says. Guides for annual adjusted operating profit of about GBP35 million, at bottom end of market expectations between GBP35 million and GBP37 million.“
Given the state of the world in general, it’s not all bad!
Some of the GSK crowd think their guys have the magic bullet. Here's hoping.. Got my AV. average down to 391, anyway.
(Had my first shares in GA then ended up with AV. I don't think AV. have ever been below 100 since their day one. Maybe someone like CU was 21p before they joined up?)
If only because it is not worth selling now.
I'd like to put in a virtual drawer and forget about it, until one day, it is either completely worthless or staged a miraculous recovery. At least it's not bought on borrowed money.
“SUNDAY 21 NOVEMBER 2021 1:36 PM
US prosecutor demands emails from Darktrace following Mike Lynch fraud case”
https://www.google.com/amp/s/www.cityam.com/us-prosecutor-demands-emails-from-darktrace-following-mike-lynch-fraud-case/%3Famp%3D1
“Next year will be a “landmark” one for GlaxoSmithKline, according to CEO Emma Walmsley — though many of the biggest changes she forecasted may not become evident until next year.“
https://www.statnews.com/2021/11/18/glaxosmithklines-emma-walmsley-predicts-a-landmark-2022-for-the-company/
“Darktrace aims to expand into ‘proactive’ security AI by end of year“
https://venturebeat.com/2021/11/16/darktrace-aims-to-expand-into-proactive-security-ai-by-end-of-year/amp/
With about 20 stocks in the p/f I see plenty that rise and fall. It's best not to panic on the dips. And even a market crash can be made into an opportunity as I proved to myself after the covid crash.
My local B&M is noticeably better stocked than the likes of Tesco, Asda and Morrisons. They are also opening a second large store in town as we approach xmas - how can stock a second store if their cupboard is bare? Appearances suggest they are well placed to compete.
" Berenberg said a visit to Darktrace’s headquarters in Cambridge last week confirmed its confidence in the group. The bank said it was shown "extensive product demonstrations and came away with a better understanding of the product and its real-world applicability".
"Management indicated that, while the focus is still on winning new customers, there has also been more focus on upsell campaigns also. These are being created by the company’s strategic marketing teams and are feeding account executives with more granular information on customer needs to drive upsell," it said.
"This, coupled with churn reducing because of an enlarged customer success team, should enable the net retention rate (NRR) rates to continue to trend upward."
Berenberg’s forecast that NRR will be fairly constant seems increasingly conservative, it said, particularly as management confirmed its two new product categories - Prevent and Heal - will be launched by the end of 2021 and 2022 respectively.
The bank said claims that Darktrace has underspent on R&D were refuted by management, who reiterated that its existing technology does not require models to be updated by large-scale cybersecurity teams and that the AI technology is "ubiquitous", meaning it can be used across the firm’s different products.
"This naturally lowers R&D spend on a relative basis. This was brought home by seeing it in person, along with the pride of the technical staff in how it is achieved," Berenberg said.
It also noted that according to Glass Door, the average salary of a software engineer at Darktrace in Cambridge is roughly half that of West Coast cyber peers, highlighting the difference in R&D expenditure.
"The argument that Darktrace is underspending on R&D therefore appears to ignore the context behind this figure," it said.
Berenberg has a 1,000 price target on the stock."
“AO World tops the list of the FTSE 350's most undervalued companies”..
“Last month the company saw its shares take a bath as it became the latest company to warn of supply chain hitches, while also bemoaning “challenging market dynamics” in both the UK and Germany.
However, the stock has a “compelling long-term growth story” and is set to benefit from recent market shifts, according to analysts at Jefferies.”
https://www.proactiveinvestors.co.uk/companies/amp/news/965010
I've 18 stocks of which 9 are in loss and both British retailers I hold are down. Today I read this about AO:
"Analysts at Jefferies reiterated their 400.0p target price on shares of AO World on Friday despite stating the firm was just another in a long line of retailers to face "challenging" 2020 comparatives.
While Jefferies noted the half had been impacted by driver shortages and supply chain disruption, more concerningly, it said, was that the competitive environment in Germany seemed to have "stepped up markedly", with revenue growth of 3% well below its full-year estimates of 35% growth.
"With AO operating close to breakeven, its ability to grow in an environment of higher COCA and lower product margins appears to have been materially constrained. While management notes the strong 2yr growth rate (+84%), we are concerned that for AO to resume its targeted growth trajectory in Germany, there will either need to be: 1) some normalisation in the competitive dynamic, or 2) margin gains from suppliers to support AO's competitive positioning," said the analysts.
"Combing through the firm's guidance, Jefferies stated AO's "unscheduled and disappointing" update implied a roughly £10.0m hit to full-year underlying earnings.
"We see the UK shortfall as fairly understandable, given well-known challenges around driver shortages, global supply chains, and the difficulties of predicting growth against demanding comparatives. The situation in Germany, however, is going to require deeper consideration - just as the model had appeared to be fixed, a new layer of competitive challenge seems to have emerged. Once again, AO has questions to answer regarding its international growth aspirations," concluded Jefferies."
At the moment I don't feel inclined to cut and run without giving it at least another 6 months but I'd like to know why they have a 400p target. On the plus side I am now nicely back in profit with GSK after waiting 6 months.